Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Core Insights - Lipella Pharmaceuticals Inc. has reported positive topline results from its Phase 2a multicenter trial of LP-310, an oral rinse formulation aimed at treating oral lichen planus (OLP), demonstrating significant reductions in pain, ulceration, and inflammation [1][5][6] - The treatment exhibited a favorable safety profile with no serious adverse events or patient dropouts, indicating good tolerability [1][6] - The trial is progressing to a higher dose cohort, with recruitment expected to conclude by mid-2025, and the company plans to present findings at the BIO CEO & Investor Conference [1][7] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for diseases with significant unmet needs, specifically targeting conditions without FDA-approved therapies [11] - The company completed its initial public offering in 2022 and aims to reformulate existing generic drugs for new applications [11] Industry Context - Oral lichen planus affects approximately 6 million Americans and is characterized by chronic inflammation of the oral mucous membranes, leading to pain and discomfort [2] - There are currently no FDA-approved therapies for OLP, highlighting the potential market opportunity for LP-310 as a targeted treatment [2][3]